Guillain-Barre Syndrome Associated with Acute Hepatitis A Infection: A Case Report

Main Article Content

Masoud Mardani
Rozita Khodashahi
Yazdanali Faghani

Abstract

Background and Aim: Guillain-Barré syndrome (GBS) is considered as an inflammatory postmanifestation of infectious, which acute ascending motor weakness, hyporeflexia or areflexia and sometimes sensory loss are hallmarks of this clinical syndrome. It is an acute polyradiculoneuropathy often provoked by an infectious agent. It is an acute polyradiculoneuropathy often provoked by an infectious agent, but its development following acute hepatitis A has rarely been reported.

Case Presentation: The authors report a 35 years old female of Guillain-Barre syndrome following acute hepatitis A in a young female, that developed symmetrically ascending motor weakness two weeks after the onset of initial symptoms of hepatitis infection. Our case presented with high-grade fever, vomiting and jaundice. The diagnosis of GBS was made according to clinical manifestations and albuminocytologic dissociation in cerebrospinal fluid. The patient was transferred in the ICU, NGT fixed, and plasmapheresis started. Patient’s neurological condition improved after 8 times plasmapheresis every 48 h after seven day in ICU. Treatment outcome was satisfactory and her facial palsy had almost completely improved.

Conclusion: Although GBS due to hepatitis A is very rar, this complication should be kept in mind and the best way to prevent Hepatitis A through vaccination and personal hygiene especially in close contact with an infected household member, beside good environmental sanitation.

Keywords:
Acute hepatitis, flaccid paralysis, hyporeflexia, infection, Guillain-Barré syndrome, weakness.

Article Details

How to Cite
Mardani, M., Khodashahi, R., & Faghani, Y. (2020). Guillain-Barre Syndrome Associated with Acute Hepatitis A Infection: A Case Report. Asian Journal of Case Reports in Medicine and Health, 3(1), 21-25. Retrieved from http://journalajcrmh.com/index.php/AJCRMH/article/view/30120
Section
Case Study

References

Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: A clinician-scientists journey. Proceedings of the Japan Academy. Series B. 2012;88(7): 299-326.

Grover B, et al. Severe viral hepatitis A infection, Landry-Guillain-Barre syndrome, and hereditary elliptocytosis. South Med J. 1986;79(2):251-2.

Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis. 2001;1 (1):29-37.

Grygorczuk S, et al. Guillain-Barre Syndrome and its association with infectious factors]. Neurol Neurochir Pol. 2005;39(3):230-6.

Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012;366 (24):2294-304.

Menon D, Jagtap SA, Nair MD, Guillain-Barre syndrome following acute viral hepatitis A. J Neurosci Rural Pract. 2014;5 (2):204-5.

Ang CW et al. cross-reactive antibodies against gm2 and cmv-infected fibroblasts in Guillain-barre syndrome. Neurology. 2000; 54(7):1453-8.

Hadden RD, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology. 2001;56(6): 758-65.

Hughes RA, et al. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol. 1999;100(1-2):74-97.

Shimoya K, et al. Guillain-Barre syndrome with high titers of anti-GM2 and anti-GalNAc-GD1a antibody following cytomegalovirus hepatitis. Rinsho Shinkeigaku. 1997;37(2):106-10.

Ono SK, Chida, Takasu T. Guillain-Barre syndrome following fulminant viral hepatitis A. Intern Med.1994;33(12):799-801.

Dimachkie MM, Barohn RJ, Guillain-Barre syndrome and variants. Neurol Clin. 2013;31(2):491-510.

Tabor E. Guillain-Barre syndrome and other neurologic syndromes in hepatitis A, B and non-A, non-B. J Med Virol. 1987;21 (3):207-16.

Willison HJ, Jacobs BC, van Doorn PA, Guillain-Barre syndrome. Lancet. 2016;388 (10045):717-27.

Letaief A, et al. Age-specific seroprevalence of hepatitis a among school children in central Tunisia. Am J Trop Med Hyg. 2005;73(1):40-3.

Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis. 1995;171(1): S2-8.